{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:12:49Z","timestamp":1788883969013,"version":"build-2803163510"},"reference-count":39,"publisher":"Bentham Science Publishers Ltd.","issue":"29","funder":[{"DOI":"10.13039\/501100001412","name":"CSIR-CDRI","doi-asserted-by":"publisher","award":["10109"],"award-info":[{"award-number":["10109"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,11,20]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Tuberculosis (TB) is a major infectious disease caused by Mycobacterium Tuberculosis.\nAs per the World Health Organization (WHO) report of 2019, there were 1.5 million deaths\nin the year 2018, mainly because of multi- and extensively drug-resistant tuberculosis (MDR &amp;\nXDR-TB). Among several antitubercular drugs in clinical trials, bedaquiline (TMC207) is a highly\npromising drug that was approved by the FDA in 2012 and marketed in 2016 for the treatment of multidrug\nresistant TB in combination with other drugs. Bedaquiline acts on mycobacterial ATP synthase and\nis highly effective in replicating as well as on dormant mycobacteria. Several series of substituted quinolines\nhave been reported with their antitubercular and ATP synthase inhibitory activity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> To understand the role of physicochemical parameters like hydrophobicity, electronic and\nsteric factors in eliciting the biological response, the Quantitative structure-activity relationship (QSAR)\nstudies have been carried out using the computed parameters as independent variable and activity (-log\nIC50\/MIC) as the dependent variable.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The developed QSAR models in terms of positively contributing Molar Refractivity (MR) and\nnegatively contributing Partition Coefficient (PC) and Connolly Molecular Area (CMA) parameters\nhave high predictivity as also shown on external data set and the mean value of the computed 3D parameters\nof enantiomers may be used in QSAR analysis for racemic compounds.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>These results are also substantiated by pharmacophore modeling. The similar dependence\nof antitubercular activity against whole-cell M.Tb.H37Rv on MR and CMA suggests ATP synthase as\nthe main target for antitubercular activity and the QSAR models may be useful in the identification of\nnovel antitubercular agents.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666200903163515","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T11:38:55Z","timestamp":1599219535000},"page":"2723-2734","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["ATP Synthase Inhibitors as Anti-tubercular Agents: QSAR Studies in Novel Substituted Quinolines"],"prefix":"10.2174","volume":"20","author":[{"given":"Anil K.","family":"Saxena","sequence":"first","affiliation":[{"name":"Division of Medicinal and Process Chemistry, CSIR- Central Drug Research Institute, Lucknow-226031, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneer","family":"Alam","sequence":"additional","affiliation":[{"name":"Division of Medicinal and Process Chemistry, CSIR- Central Drug Research Institute, Lucknow-226031, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1185449","volume":"328","author":"Dye C.","year":"2010","unstructured":"Dye C.; Williams B.G.; The population dynamics and control of tuberculosis. Science 2010,328(5980),856-861","journal-title":"Science"},{"key":"ref=2","year":"2019","unstructured":"WHO Global tuberculosis report Available from:\n                     https:\/\/www.who.int\/tb\/publications\/global_report\/en\/2019","journal-title":"WHO Global tuberculosis report"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nm0307-271a","volume":"13","author":"Mandavilli A.","year":"2007","unstructured":"Mandavilli A.; Virtually incurable TB warns of impending disaster. Nat Med 2007,13(3),271","journal-title":"Nat Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/S0140-6736(10)60410-2","volume":"375","author":"Gandhi N.R.","year":"2010","unstructured":"Gandhi N.R.; Nunn P.; Dheda K.; Schaaf H.S.; Zignol M.; van Soolingen D.; Jensen P.; Bayona J.; Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010,375(9728),1830-1843","journal-title":"Lancet"},{"key":"ref=5","year":"2017","unstructured":"World health organization. Multidrug and extensively drug resistance Tb (M\/XDR-TB),Global report on surveillance and response. Available from:  2017"},{"key":"ref=6","year":"2019","unstructured":"WHO WHO treatment guidelines for drug-resistant tuberculosis 2019","journal-title":"WHO WHO treatment guidelines for drug-resistant tuberculosis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1164\/rccm.201206-1001CI","volume":"186","author":"Seddon J.A.","year":"2012","unstructured":"Seddon J.A.; Furin J.J.; Gale M.; Del Castillo Barrientos H.; Hurtado R.M.; Amanullah F.; Ford N.; Starke J.R.; Schaaf H.S.; Sentinel Project on Pediatric Drug-Resistant Tuberculosis. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am J Respir Crit Care Med 2012,186(10),953-964","journal-title":"Am J Respir Crit Care Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nature09657","volume":"469","author":"Koul A.","year":"2011","unstructured":"Koul A.; Arnoult E.; Lounis N.; Guillemont J.; Andries K.; The challenge of new drug discovery for tuberculosis. Nature 2011,469(7331),483-490","journal-title":"Nature"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(10)60359-9","volume":"375","author":"Ma Z.","year":"2010","unstructured":"Ma Z.; Lienhardt C.; McIlleron H.; Nunn A.J.; Wang X.; Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010,375(9731),2100-2109","journal-title":"Lancet"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/1062936X.2017.1419375","volume":"29","author":"Nandi S.","year":"2018","unstructured":"Nandi S.; Ahmed S.; Saxena A.K.; Combinatorial design and virtual screening of potent anti-tubercular fluoroquinolone and isothiazoloquinolone compounds utilizing QSAR and pharmacophore modelling. SAR QSAR Environ Res 2018,29(2),151-170","journal-title":"SAR QSAR Environ Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2174\/1568026619666190219105722","volume":"19","author":"Saxena A.K.","year":"2019","unstructured":"Saxena A.K.; Singh A.; Mycobacterial tuberculosis Enzyme Targets and their Inhibitors. Curr Top Med Chem 2019,19(5),337-355","journal-title":"Curr Top Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1016\/j.bmcl.2011.06.076","volume":"21","author":"Roy K.K.","year":"2011","unstructured":"Roy K.K.; Singh S.; Sharma S.K.; Srivastava R.; Chaturvedi V.; Saxena A.K.; Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H37Rv. Bioorg Med Chem Lett 2011,21(18),5589-5593","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijantimicag.2013.03.007","volume":"42","author":"Saxena A.K.","year":"2013","unstructured":"Saxena A.K.; Roy K.K.; Singh S.; Vishnoi S.P.; Kumar A.; Kashyap V.K.; Kremer L.; Srivastava R.; Srivastava B.S.; Identification and characterisation of small-molecule inhibitors of Rv3097c-encoded lipase (LipY) of Mycobacterium tuberculosis that selectively inhibit growth of bacilli in hypoxia. Int J Antimicrob Agents 2013,42(1),27-35","journal-title":"Int J Antimicrob Agents"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ijantimicag.2012.09.012","volume":"41","author":"Khan S.R.","year":"2013","unstructured":"Khan S.R.; Singh S.; Roy K.K.; Akhtar M.S.; Saxena A.K.; Krishnan M.Y.; Biological evaluation of novel substituted chloroquinolines targeting mycobacterial ATP synthase. Int J Antimicrob Agents 2013,41(1),41-46","journal-title":"Int J Antimicrob Agents"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1016\/j.bmcl.2013.02.030","volume":"23","author":"Kumar S.","year":"2013","unstructured":"Kumar S.; Dwivedi A.P.; Kashyap V.K.; Saxena A.K.; Dwivedi A.K.; Srivastava R.; Sahu D.P.; Synthesis and biological evaluation of trans 6-methoxy-1,1-dimethyl-2-phenyl-3-aryl-2,3-dihydro-1H-inden-4-yloxyalkylamine derivatives against drug susceptible, non-replicating M. tuberculosis H37Rv and clinical multidrug resistant strains. Bioorg Med Chem Lett 2013,23(8),2404-2407","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=16","year":"2013","unstructured":"FDA Bedaquiline receives accelerated approval from the fda for mdr-tb rx  Avaialble from: \n                     ext-link-type=\"uri\" xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.fda.gov\/news\/Events\/Newsroom\/PressAnnouncements\/ucm333695.htm\">http:\/\/www.fda.gov\/news\/Events\/Newsroom\/PressAnnouncements\/ucm333695.htm2013","journal-title":"FDA Bedaquiline receives accelerated approval from the fda for mdr-tb rx"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nchembio884","volume":"3","author":"Koul A.","year":"2007","unstructured":"Koul A.; Dendouga N.; Vergauwen K.; Molenberghs B.; Vranckx L.; Willebrords R.; Ristic Z.; Lill H.; Dorange I.; Guillemont J.; Bald D.; Andries K.; Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat Chem Biol 2007,3(6),323-324","journal-title":"Nat Chem Biol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"25273","DOI":"10.1074\/jbc.M803899200","volume":"283","author":"Koul A.","year":"2008","unstructured":"Koul A.; Vranckx L.; Dendouga N.; Balemans W.; Van den Wyngaert I.; Vergauwen K.; G\u00f6hlmann H.W.; Willebrords R.; Poncelet A.; Guillemont J.; Bald D.; Andries K.; Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008,283(37),25273-25280","journal-title":"J Biol Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"11945","DOI":"10.1073\/pnas.0711697105","volume":"105","author":"Rao S.P.","year":"2008","unstructured":"Rao S.P.; Alonso S.; Rand L.; Dick T.; Pethe K.; The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2008,105(33),11945-11950","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jyp.2013.12.002","volume":"5","author":"Lakshmanan M.","year":"2013","unstructured":"Lakshmanan M.; Xavier A.S.; Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm 2013,5(4),112-115","journal-title":"J Young Pharm"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1042\/BST20130101","volume":"41","author":"B\u00f6rsch M.","year":"2013","unstructured":"B\u00f6rsch M.; Duncan T.M.; Spotlighting motors and controls of single FoF1-ATP synthase. Biochem Soc Trans 2013,41(5),1219-1226","journal-title":"Biochem Soc Trans"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/iub.1120","volume":"65","author":"Iino R.","year":"2013","unstructured":"Iino R.; Noji H.; Operation mechanism of F(o) F(1)-adenosine triphosphate synthase revealed by its structure and dynamics. IUBMB Life 2013,65(3),238-246","journal-title":"IUBMB Life"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BST20110773","volume":"41","author":"Walker J.E.","year":"2013","unstructured":"Walker J.E.; The ATP synthase: the understood, the uncertain and the unknown. Biochem Soc Trans 2013,41(1),1-16","journal-title":"Biochem Soc Trans"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"15629","DOI":"10.1073\/pnas.0507850102","volume":"102","author":"Shi L.","year":"2005","unstructured":"Shi L.; Sohaskey C.D.; Kana B.D.; Dawes S.; North R.J.; Mizrahi V.; Gennaro M.L.; Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and under in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci USA 2005,102(43),15629-15634","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=25","first-page":"204","year":"2014","unstructured":"Treatment of patients with MDR-TB. Briefing document, TMC 207 (bedaquiline) Anti-infective Drugs Advisory Committee. NDA,\n                     2014,204-384"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tube.2014.04.001","volume":"94","author":"Kakkar A.K.","year":"2014","unstructured":"Kakkar A.K.; Dahiya N.; Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis (Edinb) 2014,94(4),357-362","journal-title":"Tuberculosis (Edinb)"},{"key":"ref=27","author":"Mesens N.","year":"2007","unstructured":"Mesens N.; Verbeeck J.; Rouan M.; Vanparys P.; Elucidating the role of M2 in the preclinical safety profile of TMC207. Abstract on the 38th Union World Conference on Lung Health, Cape Town, South Africa,  2007"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.4155\/fmc.11.79","volume":"3","author":"Guillemont J.","year":"2011","unstructured":"Guillemont J.; Meyer C.; Poncelet A.; Bourdrez X.; Andries K.; Diarylquinolines, synthesis pathways and quantitative structure--activity relationship studies leading to the discovery of TMC207. Future Med Chem 2011,3(11),1345-1360","journal-title":"Future Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bmc.2014.12.060","volume":"23","author":"Singh S.","year":"2015","unstructured":"Singh S.; Roy K.K.; Khan S.R.; Kashyap V.K.; Sharma A.; Jaiswal S.; Sharma S.K.; Krishnan M.Y.; Chaturvedi V.; Lal J.; Sinha S.; Dasgupta A.; Srivastava R.; Saxena A.K.; Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. Bioorg Med Chem 2015,23(4),742-752","journal-title":"Bioorg Med Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1039\/C5MD00131E","author":"Kaliaa D.","year":"2015","unstructured":"Kaliaa D.; Kumar A.; Meenaa G.; Sethia K.P.; Sharma R.; Trivedi P.; Khan S.R.; Singh A.; Sinhg A.S.; Sharma S.; Roy K.K.; Kant R.; Krishnan M.Y.; Singh B.N.; Sinha S.; Chaturvedi V.; Saxena A.K.; Dikshit D.K.; Synthesis and anti-tubercular activity of conformationally-constrained and bisquinoline analogs of TMC207 Med. Chem Commun 2015,1554-1563","journal-title":"Chem Commun"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.pbiomolbio.2019.11.006","volume":"152","author":"Kamariah N.","year":"2020","unstructured":"Kamariah N.; Ragunathan P.; Shin J.; Saw W.G.; Wong C.F.; Dick T.; Gr\u00fcber G.; Unique structural and mechanistic properties of mycobacterial F-ATP synthases: Implications for drug design. Prog Biophys Mol Biol 2020,152,64-73","journal-title":"Prog Biophys Mol Biol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"13649","DOI":"10.1021\/ja0697875","volume":"128","author":"Mills N.","year":"2006","unstructured":"Mills N.; ChemDraw Ultra 10.0. J Am Chem Soc 2006,128,13649-13650","journal-title":"J Am Chem Soc"},{"key":"ref=33","unstructured":"Minitab Ltd. Available from:"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/1062936X.2019.1588159","volume":"30","author":"Sanyal S.","year":"2019","unstructured":"Sanyal S.; Amin S.A.; Adhikari N.; Jha T.; QSAR modelling on a series of arylsulfonamide-based hydroxamates as potent MMP-2 inhibitors. SAR QSAR Environ Res 2019,30(4),247-263","journal-title":"SAR QSAR Environ Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1080\/1062936X.2017.1331467","volume":"28","author":"Bitam S.","year":"2017","unstructured":"Bitam S.; Hamadache M.; Hanini S.; QSAR model for prediction of the therapeutic potency of N-benzylpiperidine derivatives as AChE inhibitors. SAR QSAR Environ Res 2017,28(6),471-489","journal-title":"SAR QSAR Environ Res"},{"key":"ref=36","first-page":"560","volume":"109","author":"Erbil Y.","year":"2018","unstructured":"Erbil Y.; Babaarslan O.; Ilhan I.; A comparative prediction for tensile properties of ternary blended open-end rotor yarns using regression and neural network models. SAR QSAR Environ Res 2018,109(4),560-568","journal-title":"SAR QSAR Environ Res"},{"key":"ref=37","author":"Schr\u00f6dinger L.L.C.","year":"2009","unstructured":"Schr\u00f6dinger L.L.C.;  Phase, version 31 2009","journal-title":"Phase, version 31"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/026119290503300508","volume":"33","author":"Jaworska J.","year":"2005","unstructured":"Jaworska J.; Nikolova-Jeliazkova N.; Aldenberg T.; QSAR applicabilty domain estimation by projection of the training set descriptor space: a review. Altern Lab Anim 2005,33(5),445-459","journal-title":"Altern Lab Anim"},{"key":"ref=39","unstructured":"OECD principles for the validation, for regulatory purposes, of (quantitative) structure-activity relationship models. Available from:"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185550","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185550\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,3]],"date-time":"2021-07-03T05:17:49Z","timestamp":1625289469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185550\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":39,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2020,11,20]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666200903163515","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}